Salam ABBARA

Dr. Salam ABBARA

Pasteur Institute Paris
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
SASalam ABBARA
Salam ABBARA
GGGilles Grateau
Gilles Grateau
SDStéphanie Ducharme-Bénard
Stéphanie Ducharme-Bénard
DSDavid Saadoun
David Saadoun
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle
Certain types of vasculitis occur more frequently and present differently in patients with familial Mediterranean fever (FMF). We assessed the characteristics of patients with FMF and systemic vasculitis through a systematic review of the literature. Medline was searched by two independent investigators until December 2017. We screened 310 articles and selected 58 of them (IgA vasculitis n = 12, polyarteritis nodosa (PAN) n = 25, Behçet's disease (BD) n = 7, other vasculitis n = 14). Clinical case reports were available for 167 patients (IgA vasculitis n = 46, PAN n = 61, BD n = 46, other vasculitis n = 14), and unavailable for 45 patients (IgA vasculitis n = 38, PAN n = 7). IgA vasculitis was the most common vasculitis in FMF patients with a prevalence of 2.7–7%, followed by PAN with a prevalence of 0.9–1.4%. Characteristics of FMF did not differ between patients with and without vasculitis. Patients with FMF and IgA vasculitis displayed more intussusception (8.7%) and possibly less IgA deposits on histological analysis than patients with IgA vasculitis alone. Patients with FMF and PAN had a younger age at vasculitis onset (mean age = 17.9 years), as well as more perirenal hematomas (49%) and CNS involvement (31%) than patients with PAN alone. Glomerular involvement was noted in 33% of patients diagnosed with PAN, suggesting an alternative diagnosis. Sequencing of the MEFV gene confirmed the presence of two pathogenic variants in 73% of FMF patients with IgA vasculitis or PAN. The majority of patients with BD were from one case series, and presented more skin, gastrointestinal, and CNS involvement than patients with isolated BD. In conclusion, FMF, particularly when supported by two pathogenic MEFV mutations, could predispose to IgA vasculitis, or a PAN-like vasculitis with more perirenal bleeding and CNS involvement.

1 May 2018 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
FAFleur Cohen Aubart
Fleur Cohen Aubart
SASalam ABBARA
Salam ABBARA
TMThierry Maisonobe
Thierry Maisonobe
VCVincent Cottin
Vincent Cottin
TPThomas Papo
Thomas Papo
DVDominique Valeyre
Dominique Valeyre
Objectives To describe clinicopathologic features of muscular sarcoidosis and the associated sarcoidosis phenotype through a nationwide multicenter study. Methods Patients were included if they had histologically proven sarcoidosis and symptomatic muscular involvement confirmed by biological, imaging, or histologic examinations. Results Forty-eight patients (20 males) were studied, with a median age at muscular symptoms onset of 45 years (range 18–71). Four patterns were identified: a nodular pattern (27%); smoldering phenotype (29%); acute, subacute, or progressive myopathic type (35%); and combined myopathic and neurogenic pattern (10%). In all patterns, sarcoidosis was multivisceral with a median of 3 extramuscular organs involved (mostly lungs, lymph nodes, eyes, and skin) and a prolonged course with long-term use of corticosteroids and immunosuppressive drugs. Muscular patterns differed according to clinical presentation (myalgia, nodules, or weakness), electromyographic findings, muscular MRI, and response to sarcoidosis treatment. The myopathic and neuromuscular patterns were more severe. Conclusion This nationwide study of muscular sarcoidosis allowed the identification of 4 patterns of granulomatous myositis, which differed by phenotypes and the clinical course.

1 April 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SASalam ABBARA
Salam ABBARA
APAurélia Pitsch
Aurélia Pitsch
SJSébastien Jochmans
Sébastien Jochmans
KHKyann Hodjat
Kyann Hodjat
PCPascale Cherrier
Pascale Cherrier
SDSylvain Diamantis
Sylvain Diamantis

1 September 2019 in RMD Open
Verified
Journal Article
Open access
PDF file
SASalam ABBARA
Salam ABBARA
RSRaphaele Seror
Raphaele Seror
JHJulien Henry
Julien Henry
PCPascale Chretien
Pascale Chretien
AGAude Gleizes
Aude Gleizes
GNGaetane Nocturne
Gaetane Nocturne
Objectives To describe and compare the clinical and biological characteristics of subjects with primary Sjögren’s syndrome (pSS) with and without anti-RNP antibodies. Methods Patients fulfilling the American College of Rheumatology (ACR)/EULAR 2016 criteria for pSS and having anti-RNP antibodies, without other connective tissue disease diagnosed and no anti-dsDNA antibodies were retrieved from the database from our French National Reference Center. These patients were compared with all other patients with pSS with negative anti-Sm, anti-RNP and anti-dsDNA antibodies. Results Overall, 21 patients with pSS positive for anti-RNP antibodies and 446 negative for anti-RNP antibodies were retrieved. Anti-RNP-positive patients had a lower median age at onset of pSS symptoms (41.0 vs 50.0 years, p=0.01), a higher median EULAR Sjögren’s syndrome disease activity index at inclusion (8.0 vs 3.0, p<0.01), more frequently constitutional symptoms (14.3% vs 0.01%, p<0.01), myositis (19.0% vs 2.3%, p<0.01) and pulmonary (19.0% vs 5.7%, p=0.04) involvement. Moreover, anti-RNP-positive patients had higher median gammaglobulin levels (22.5 vs 13 g/L, p<0.01), more frequently anti-SSA antibodies (90.5% vs 67.1%, p=0.03), but less frequent lymphocytic sialadenitis with a focus score ≥1 (66.7% vs 85.5%, p=0.03). If the analysis is restricted to anti-SSA-positive patients, anti-RNP positivity is associated with the same clinicobiologic features except the pulmonary involvement. Conclusion Patients with pSS with anti-RNP antibodies displayed a more active systemic disease, with more frequent muscular and pulmonary involvement, and increased gammaglobulin level, compared with anti-RNP-negative patients.

1 March 2017 in Joint Bone Spine
Verified
Journal Article
Closed access
SASalam ABBARA
Salam ABBARA
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle
KSKatia Stankovic Stojanovic
Katia Stankovic Stojanovic
CBClaude Bachmeyer
Claude Bachmeyer
PSPatricia Senet
Patricia Senet
GGGilles Grateau
Gilles Grateau

2 July 2025 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
AAAbdulaziz Alhazmi
Abdulaziz Alhazmi
AKABRAHAM KATIME
ABRAHAM KATIME
AHAhneez Abdul Hameed
Ahneez Abdul Hameed
AMAlejandra Morales
Alejandra Morales
ESEsgitm Slamvi
Esgitm Slamvi